Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.